Myasthenia Gravis Clinical Trials in Detroit, Michigan
8 recruitingDetroit, Michigan
Showing 1–8 of 8 trials
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Immunovant Sciences GmbH231 enrolled84 locationsNCT07039916
Recruiting
Phase 2
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled15 locationsNCT07284420
Recruiting
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Myasthenia GravisGeneralized Myasthenia Gravis (gMG)Generalized Myasthenia Gravis+3 more
argenx70 enrolled18 locationsNCT07294170
Recruiting
Phase 3
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Myasthenia Gravis
Janssen Research & Development, LLC115 enrolled14 locationsNCT07217587
Recruiting
Phase 3
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Generalized Myasthenia Gravis
Novartis Pharmaceuticals146 enrolled124 locationsNCT06517758
Recruiting
Phase 4
A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)
New Onset Generalized Myasthenia Gravis (gMG)
argenx30 enrolled18 locationsNCT06909214
Recruiting
Phase 1
A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
Myasthenia GravisMuscle WeaknessAutoimmune Diseases+4 more
Arcellx, Inc.30 enrolled13 locationsNCT06626919
Recruiting
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Myasthenia Gravis
argenx680 enrolled35 locationsNCT06298565